Skip to NavigationSkip to content

News

0
The bid is expected to top Sanofi’s $9.3 billion cash offer last week
0
The separate publicly traded company will be anchored by existing products, Eloctate and Alprolix
0
Discussions extended by a week to reach agreement on price for Duchenne Muscular Dystrophy drug 
0
Says now sees full-year earnings between $2.38 and $2.48 a share 

Features

Medicins Sans Frontieres takes a stand against Pfizer’s filing of an Indian patent on a highly effective pneumonia vaccine.